The mobile version of the Asarina Pharma website is under construction. For the best experience, please use a desktop when browsing.

Giacevo nel letto in uno stupore, il mio cuore batteva nelle informazioni per te mie orecchie e il mio respiro era superficiale e lacero.

REMAIN IN CONTROL OF YOUR LIFE

You may not have heard of ‘Allopregnanolone’, but you could well care for one of the millions who suffer from its effects.

From Tourette syndrome to OCD, PTSD, stress-related fatigue, compulsive gambling, addiction and PMDD—the potent neurosteroid Allopregnanolone is implicated in them all.

Our novel treatment Sepranolone is the endogenous compound that modulates the effects of Allopregnanolone. It has been developed from over 40 years’ neuroendocrinological research.

Home / Menstrual migraine / Sepranolone & menstrual migraine

SEPRANOLONE & MENSTRUAL MIGRAINE

Latest Press Release

Asarina Pharma carries out a directed share issue following a request for loan conversion from Östersjöstiftelsen

2022-06-23 09:15 UTC

Solna, 23 June 2022. The Board of Directors of Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”) has resolved on a directed issue of 3,896,885 shares to Östersjöstiftelsen (ÖSS) following a request for conversion in accordance with convertible loan agreement between Asarina Pharma and ÖSS entered into in May 2021.

SAVE THE DATE: Asarina Pharma R&D Day – Thursday 26 March

2020-02-05 14:09 UTC

CORRECTION: Asarina Pharma AB (publ) (ASAP: FN Stockholm) invites institutional investors, financial analysts and media to an R&D Day in Stockholm on THURSDAY 26 MARCH 2020 (not Weds 26 March as published earlier 0700 UTC, 4 February.)

“I believe Sepranolone will always attract interest from clinicians and patients, whatever indication it is launched for.”

Professor Marie Bixo, University of Umeå

The neurochemical GABA is the brain’s most powerful inhibitory neurotransmitter. It plays a crucial role in inhibiting and reducing stress, fear and anxiety levels. But what keeps GABA in check? The neurosteroid Allopregnanolone (or ALLO) is a potent modulator of GABA, acting on the GABA-A receptor, a major pathway for GABA within the brain.

The body’s endogenous compound—Sepranolone—regulates and modulates the negative effects of ALLO. Asarina Pharma is the first company to have developed and synthesized Sepranolone as a medication, patenting a pharmaceutical formulation in 2010.

Sepranolone has achieved an excellent safety profile in substantial clinical trials and will be tested in a Tourette syndrome study in 2021.

TOURETTE SYNDROME

“I believe we are on the crest of a new wave of understanding of just how broad the impact of Allopregnanolone really is. Compulsivity impacts on so many different conditions, from ADHD and OCD/B through to eating disorders and addiction.”

Assoc prof Marco Bortolato, University of Utah

Tourette’s syndrome is a cruel condition typically striking first between the ages of 3 – 9 years old. Yet many current treatments, like the anti-psychotic Haldol, have severe side effects ranging from blurred vision, nausea and diarrhoea to involuntary movement disorder, irregular heartbeat and even renal failure.

Sepranolone: A safer approach

In May 2019 Asarina Pharma demonstrated in a preclinical animal study that Sepranolone reduced tics on a par with Haldol, without inducing any motor side effects.
Asarina Pharma CEO Peter Nordkild: “This is a new approach, and a safe one. There are no neurosteroid-based medications currently being used to treat TS. A positive result would be extremely promising for patients, and indicate that Sepranolone could potentially play a part in treating a range of other ALLO-related stress disorders.”

OBSESSIVE-COMPULSIVE DISORDER

“OCD ‘turns dust into dynamite’ they say, it’s true for me. Even though I tell myself ‘this isn’t me, it’s the OCD’, the heaviness, the panic, can be totally overwhelming”

‘Helena’ 24, Sweden.

OCD strikes as many as 12 in every 1,000 people (1.2% of the population), with slightly more women than men affected. The impact can be devastating – with a disproportionately high number of OCD cases, about 50%, classified as severe, and less than a quarter classed as mild (OCD UK).

Lack of pharmaceutical treatment options

Yet despite its prevalence and impact, treatment options, particularly pharmaceutical ones, leave many needs unmet. ERP (exposure and response therapy), today’s front-line treatment, can work well, but is demandingand time-consuming. Relapse is common. Meanwhile, SSRIs, today’s most commonly prescribed pharma treatment, have an overall efficacy of < 50%.

Asarina Pharma’s safe, endogenous compound Sepranolone represents a new approach to treating OCD.